<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908620</url>
  </required_header>
  <id_info>
    <org_study_id>C-002</org_study_id>
    <nct_id>NCT02908620</nct_id>
  </id_info>
  <brief_title>Experimental Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray in Normal Volunteers</brief_title>
  <official_title>A Double-blind, Partial Cross-over, Incomplete Factorial Study to Assess the Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray (CTY-5339-A) When Applied to the Cheek Mucosal Tissue in Normal Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cetylite Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cetylite Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the topical application to cheek tissue of the
      combination of benzocaine and tetracaine has a longer duration of local anesthetic activity
      than benzocaine alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a blinded study, either benzocaine alone of the combination of benzocaine and tetracaine
      will be sprayed onto the cheek mucosal tissue. Onset and duration of local anesthesia will be
      evaluated over a one hour period using pin prick and QST heat stimulation. Subjects will
      receive both treatments in a cross-over design with each session separated by 5-7 days. A
      total of 76 subjects (normal volunteers) will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2016</start_date>
  <completion_date type="Actual">June 7, 2017</completion_date>
  <primary_completion_date type="Actual">April 2, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of anesthesia as measured by Pin Prick Test (PPT) for one spray CTY-5339-A compared to the one spray CTY-5339-CB</measure>
    <time_frame>Change in pain assessment from baseline (time of application) up to one hour post-application</time_frame>
    <description>Assessments will be made over a period of one hour, with assessments at 1 minute intervals for the first 5 minutes and then every 5 minutes after that.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of anesthesia as measured by QST Heat for one spray CTY-5339-A compared to the one spray CTY-5339-CB</measure>
    <time_frame>Change in pain assessment from baseline (time of application) up to one hour post-application</time_frame>
    <description>Assessments will be made over a period of one hour, with assessments at 1 minute intervals for the first 5 minutes and then every 5 minutes after that.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of anesthesia (PPT) for two sprays of CTY-5339-A compared to one spray of CTY-5339-CB plus CTY-5339-P</measure>
    <time_frame>Time of application up to one hour post-application</time_frame>
    <description>Assessments will be made over a period of one hour, with assessments at 1 minute intervals for the first 5 minutes and then every 5 minutes after that.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of anesthesia (QST Heat) for two sprays of CTY-5339-A compared to one spray of CTY-5339-CB plus CTY-5339-P</measure>
    <time_frame>Time of application up to one hour post-application</time_frame>
    <description>Assessments will be made over a period of one hour, with assessments at 1 minute intervals for the first 5 minutes and then every 5 minutes after that.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of anesthesia (PPT) for two sprays of CTY-5339-A compared to one spray of CTY-5339-A</measure>
    <time_frame>Time of application up to one hour post-application</time_frame>
    <description>Assessments will be made over a period of one hour, with assessments at 1 minute intervals for the first 5 minutes and then every 5 minutes after that.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of anesthesia (QST Heat) for the two sprays of CTY-5339-A compared to one spray of CTY-5339A</measure>
    <time_frame>Time of application up to one hour post-application</time_frame>
    <description>Assessments will be made over a period of one hour, with assessments at 1 minute intervals for the first 5 minutes and then every 5 minutes after that.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of anesthesia for PPT</measure>
    <time_frame>Time of application up to one hour post-application</time_frame>
    <description>Assessments will be made over a period of one hour, with assessments at 1 minute intervals for the first 5 minutes and then every 5 minutes after that.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of anesthesia for QST Heat</measure>
    <time_frame>Time of application up to one hour post-application</time_frame>
    <description>Assessments will be made over a period of one hour, with assessments at 1 minute intervals for the first 5 minutes and then every 5 minutes after that.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders for PPT for duration</measure>
    <time_frame>Time of application up to one hour post-application</time_frame>
    <description>Assessments will be made over a period of one hour, with assessments at 1 minute intervals for the first 5 minutes and then every 5 minutes after that.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders for QST Heat for onset</measure>
    <time_frame>Time of application up to one hour post-application</time_frame>
    <description>Assessments will be made over a period of one hour, with assessments at 1 minute intervals for the first 5 minutes and then every 5 minutes after that.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders for QST Heat for duration</measure>
    <time_frame>Time of application up to one hour post-application</time_frame>
    <description>Assessments will be made over a period of one hour, with assessments at 1 minute intervals for the first 5 minutes and then every 5 minutes after that.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders for PPT at each time point</measure>
    <time_frame>Time of application up to one hour post-application</time_frame>
    <description>Assessments will be made over a period of one hour, with assessments at 1 minute intervals for the first 5 minutes and then every 5 minutes after that.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders for QST Heat at each time point</measure>
    <time_frame>Time of application up to one hour post-application</time_frame>
    <description>Assessments will be made over a period of one hour, with assessments at 1 minute intervals for the first 5 minutes and then every 5 minutes after that.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders for PPT for onset</measure>
    <time_frame>Time of application up to one hour post-application</time_frame>
    <description>Assessments will be made over a period of one hour, with assessments at 1 minute intervals for the first 5 minutes and then every 5 minutes after that.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>CTY-5339-A 1 Spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benzocaine and Tetracaine 14.0% Benzocaine, USP = 28 mg 2.0% Tetracaine Hydrochloride, USP = 4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTY-5339-A 2 Sprays</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benzocaine and Tetracaine 14.0% Benzocaine, USP = 56 mg 2.0% Tetracaine Hydrochloride, USP = 8 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTY-5339-CB 1 Spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Benzocaine only 14.0% Benzocaine, USP = 28 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzocaine and Tetracaine</intervention_name>
    <description>A single application of either 1 or 2 sprays of a combination of benzocaine 14% and tetracaine 2% with a total dose of benzocaine 28 mg and tetracaine 2 mg per spray.
The control treatment is benzocaine 14% alone with a total dose of 28 mg.</description>
    <arm_group_label>CTY-5339-A 1 Spray</arm_group_label>
    <arm_group_label>CTY-5339-A 2 Sprays</arm_group_label>
    <other_name>CTY-5339-A</other_name>
    <other_name>CTY-5339 Anesthetic Spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzocaine only</intervention_name>
    <description>Benzocaine 14% alone 200 uL (1 spray)</description>
    <arm_group_label>CTY-5339-CB 1 Spray</arm_group_label>
    <other_name>CTY-5339-CB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects between 18-75 years of age with a Body Mass Index (BMI) â‰¤32;

          -  Subjects are ASA Category I or II and are in normal physical health as judged by
             physical and laboratory examinations;

          -  Subjects with normal appearance of the oral mucosal tissues;

          -  Subjects must agree to refrain from ingesting any systemic or topical analgesic
             medication for 3 days or 5 half-lives of the drug prior to and during the study period
             and alcohol for 1 day prior to and during the study period;

          -  Subjects must agree to refrain from using mouth rinses, cough drops or throat lozenges
             on the day of each test session;

          -  Female subjects must be physically incapable of childbearing potential (postmenopausal
             for more than 1 year or surgically sterile) or practicing an acceptable method of
             contraception (hormonal, barrier with spermicide, intrauterine device, vasectomized or
             same sex partner, or abstinence). Subjects using hormonal birth control must have been
             on a stable dose of treatment for at least 30 days and received at least 1 cycle of
             treatment prior to randomization. At Screening and at Baseline of both sessions, all
             females of childbearing potential must have a negative urine pregnancy test and not be
             breastfeeding;

          -  Negative urine drug screen for drugs of abuse at Screening and at Baseline for each
             Study Session. A positive drug screen result may be permitted if the subject has been
             on a stable dose of an allowed medication for &gt;30 days;

          -  The subject is capable of reading, comprehending, and signing the informed consent
             form.

        Exclusion Criteria:

          -  Subjects with a history of any significant hepatic, renal, endocrine, cardiac,
             neurological, psychiatric, gastrointestinal, pulmonary, hematologic, or metabolic
             disorders, including glaucoma, diabetes, emphysema, and chronic bronchitis;

          -  Subjects with a history of any type of cancer other than skin related cancers;

          -  Subjects with conditions that affect the absorption, metabolism, or passage of drugs
             out of the body, (e.g., sprue, celiac disease, Crohn's disease, colitis, or liver,
             kidney, or thyroid conditions);

          -  Subjects with any history of alcohol or substance abuse (including a positive drug
             screen test);

          -  Subjects that currently have or have a history of uncontrolled hypertension;

          -  Subjects with a known hypersensitivity to any local anesthetic drug;

          -  Subjects with a hematocrit level significantly below the normal range on the screening
             laboratory examination (as judged by the PI);

          -  Subjects with any clinically significant abnormal lab result (as judged by the PI);

          -  Subjects with any condition or history felt by the Investigator to place the subject
             at increased risk;

          -  Subjects who have smoked or chewed tobacco-containing substances within 6 months prior
             to the start of the study;

          -  Subjects judged by the Investigator to be unable or unwilling to comply with the
             requirements of the protocol;

          -  Subjects who have used an investigational drug within 30 days prior to entering the
             study;

          -  Subjects who have donated blood within 3 months prior to the start of the study;

          -  Subjects who have previously participated in the trial;

          -  Subjects who are members of the study site staff directly involved with the study or a
             relative of the Sponsor or other personnel involved with the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot V Hersh, DMD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania, School of Dental Medicine Department of Oral &amp; Maxillofacial Surgery</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Tetracaine</mesh_term>
    <mesh_term>Benzocaine</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>March 23, 2018</submitted>
    <returned>April 23, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

